An antagonist of CD-47, C-MYC 42 and VEGF 43 as well as a reactivator of silenced p53 44 that is associated with both tumor cytotoxicity and normal tissue protection including protection from platinum-based myelotoxicity 45, RRx-001 is in a Phase 3 trial called REPLATINUM (NCT03699956) as a combined cytotoxic/myeloprotectant in third line and beyond SCLC.46 This evidence concerns the gene CD47 and neoplasm.